Fig. 5: SHIV challenge outcomes in IDLV-CH505 +/− protein vaccinated animals. | npj Vaccines

Fig. 5: SHIV challenge outcomes in IDLV-CH505 +/− protein vaccinated animals.

From: Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs

Fig. 5: SHIV challenge outcomes in IDLV-CH505 +/− protein vaccinated animals.

a Six weeks after completion of the scheduled vaccinations (week 117) the 16 macaques in the B1 and B2 vaccine groups and the 11 macaques in the B3 control group were challenged intrarectally with the Clade C tier 2 SHIV.CH505.375H.dCT. The four animals in group A were challenged once intravenously. The Kaplan–Meier plot shows the percentage of uninfected macaques after 10 weekly IR challenges in each group. b Peak viral load of the infected macaques from the vaccine and control groups. Lines indicate geometric means (p = 0.0506, Exact-Wilcoxon test). c–e Viral load trends from time to infection in each group. Each line represents one animal.

Back to article page